Category survey

Optogenetically-controlled restoration of muscle function in ALS model mice using engrafted ES-derived motor neurons Investments < €500k United Kingdom 2016    

New humanised delta-14 mouse model for dissecting the pathobiology of FUS-ALS Investments < €500k United Kingdom 2016    

Investigating novel protective mechanisms in motor neurons Investments < €500k United Kingdom 2016    

Cell-targeted phenotyping: using optogenetics to study ALS patient-derived motor neurons Investments < €500k United Kingdom 2016    

Motor axon stabilisation in zebrafish and models of motor neuron disease Investments < €500k United Kingdom 2016    

Molecular mechanisms of C9ORF72 repeat expansion toxicity in motor neurone disease Investments < €500k United Kingdom 2016    

Development of a C9orf72 transgenic zebrafish model of ALS Investments < €500k United Kingdom 2016    

Role of mitochondria in C9ORF72-related ALS/MND Investments < €500k United Kingdom 2016    

Whole genome sequencing of DNA samples – Birmingham Investments < €500k United Kingdom 2016    

Whole genome sequencing of DNA samples – King’s, London Investments < €500k United Kingdom 2016    

Whole genome sequencing of DNA samples – Sheffield Investments < €500k United Kingdom 2016    

Investigating deficits of axonal RNA metabolism and axonal signalling in amyotrophic lateral sclerosis Investments < €500k United Kingdom 2016    

Investigating the role of autophagy and the UPS in TDP-ALS Investments < €500k United Kingdom 2016    

“EPSRC – NIHR HTC Partnership Award: Partnership with the MindTech HTC Investments < €500k United Kingdom 2016    

Establishing an Approach for the Selection and Design of Secondary Structure Mimetics to Antagonise Protein-protein Interactions. Investments < €500k United Kingdom 2016    

Interaction-based Human Motion Analysis Investments < €500k United Kingdom 2016    

A Multiobjective Evolutionary Approach to Understanding Parkinson’s Disease Investments < €500k United Kingdom 2016    

TNT: Tracking Network dynamics with Tensor factorisations. Application to the human Chronnectome in Alzheimer’s disease Investments < €500k United Kingdom 2016    

Computer simulation of metal-amyloid interaction and its role in plaque formation Investments < €500k United Kingdom 2016    

AUTOMAC: AUTOmated Mouse behAviour reCognition Investments < €500k United Kingdom 2016    

Coenzyme Q10 a potential therapeutic target for ataxia: Evaluation of therapeutic strategies Investments < €500k United Kingdom 2016    

RBFox proteins as critical determinants for cell toxicity in DRPLA and other Spinocerebellar ataxias Investments < €500k United Kingdom 2016    

Investigating cerebellar glutathione in SCA14 by MR spectroscopy in order to identify a new treatment option Investments < €500k United Kingdom 2016    

Molecular function of human senataxin protein, mutated in ataxia oculomotor apraxia type 2 (AOA2) and amyotrophic lateral sclerosis type 4 (ALS4), in the pathology of these diseases. Investments < €500k United Kingdom 2016    

Function and pathology of spatacsin/ALS5 using a novel Drosophila model Investments < €500k United Kingdom 2016    

A new conditional BAC transgenic model of C9ORF72-linked Motoneuron Disease to allow direct visualisation and analysis of impaired RNA cellular pathways Investments < €500k United Kingdom 2016    

A. Kenneth Snowman – MND Association Lectureship in Translational Neuroscience Investments < €500k United Kingdom 2016    

Investigating the mechanisms of axonal degeneration in amyotrophic lateral sclerosis using Drosophila and mouse transgenics Investments < €500k United Kingdom 2016    

The pathophysiological role of TDP-43 in amyotrophic lateral sclerosis due to C9orf72 mutations Investments < €500k United Kingdom 2016    

Characterisation of newly identified proteins that interact with the MND-causing expanded repeat in C9orf72 Investments < €500k United Kingdom 2016    

A targeted proteomic analysis for biomarkers discovery in ALS Investments < €500k United Kingdom 2016    

Studying the function of c9orf72 in amyotrophic lateral sclerosis Investments < €500k United Kingdom 2016    

Zebrafish C9orf72 loss of function models of ALS Investments < €500k United Kingdom 2016    

C-DEMQOL – Measurement of quality of life in family carers of people with dementia: development of a new instrument for evaluation Investments < €500k United Kingdom 2016    

Novel drugs for treating Alzheimer’s disease Investments < €500k United Kingdom 2016    

Deaf people with Dementia: next steps Investments < €500k United Kingdom 2016    

Lets talk about dementia Investments < €500k United Kingdom 2016    

Disseminating the START (STrAtegies for RelaTives) coping intervention for family carers of people with dementia Investments < €500k United Kingdom 2016    

An international perspective on dementia care: a Lancet Commission Investments < €500k United Kingdom 2016    

Etanercept in Alzheimer’s Disease: a randomised, placebo controlled, double-blind phase 2 trial Investments < €500k United Kingdom 2016    

Online Cognitive Behavioural Therapy (CBT) trial Investments < €500k United Kingdom 2016    

Metabolic and vascular contributors to dementia’ Investments < €500k United Kingdom 2016    

Understanding the Basis and Interaction of Non-cognitive and Cognitive Symptoms in Dementia with Lewy Bodies Investments < €500k United Kingdom 2016    

Improving prevention trials in Alzheimer’s disease through imaging Investments < €500k United Kingdom 2016    

Of Molecules, Mice and Men: exposing and understanding apolipoprotein E effects across the lifespan Investments < €500k United Kingdom 2016    

Fundamental membrane interactions of copper generated oligomers, profibrils and amyloid fibres Investments < €500k United Kingdom 2016    

Compatibility rules for glycosaminoglycan-amyloid interactions Investments < €500k United Kingdom 2016    

Role of the Amyloid Precursor Protein in the cellular phosphoinositide metabolism through its interaction with the PIKfyve complex Investments < €500k United Kingdom 2016    

Compatibility rules for glycosaminoglycan-amyloid interactions Investments < €500k United Kingdom 2016    

Determining the role of M cells in TSE agent neuroinvasion from the intestine Investments < €500k United Kingdom 2016